According to Mr. O’Donnell, “To develop a commercially viable cell therapy, companies have to consider packaging, storage, inventory management, monitoring systems, distribution, and even clinical site capabilities from the very beginning. Companies that overlook these issues until clinical trials begin can find that they have inadvertently limited their product’s scalability and commercial viability, or incurred unnecessary costs and complications downstream.”
Following his talk, Mr. O’Donnell will also participate in the round table discussion, “What does a commercially successful cell or gene therapy look like?”
The first breakout session following the plenary talks will address commercially feasible manufacturing and business models. Mr. Simpson, Fisher BioServices’ Director of Commercial Operations, will offer his insights on cold chain transport and building efficiency into operational processes, and will discuss recent case studies for allogeneic vs. autologous therapies. He will then participate in a roundtable discussion focused on minimizing the cost of goods and maximizing efficiency of operations.
About Fisher BioServices
Fisher BioServices has 25 years of experience in biological repository/biobanking services, cold chain logistics, and in supporting clinical trials and public health research. The company manages more than 170,000,000 high value biological specimens, cell-based therapeutics, vaccines, tissues, and sample-related data. Fisher BioServices has cGMP compliant repositories, laboratories, and specimen collection kit production and clinical trial support capabilities, depots, and affiliated sites around the world, and serves more than 20 government and hundreds of commercial clients. Fisher BioServices is part of Thermo Fisher Scientific, Inc., the world leader in serving science.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science. The comp
Page: 1 2 3 Related biology technology :1
Copyright©2012 Vocus, Inc.
All rights reserved
. ORNL wins 9 R&D 100s, bringing total to 1732
. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies3
. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah4
. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease5
. BioRestorative Therapies Retains KCSA Strategic Communications as Investor Relations Counsel6
. BioRestorative Therapies Obtains $2.1 Million in 2012 Private Financing7
. BioRestorative Therapies Announces Closing of License Agreement for Adult Stem Cell Disc/Spine Procedure8
. BioRestorative Therapies Announces Next Generation of Stem Cell Disc Delivery Device9
. CNIO researchers describe a new target for developing anti-angiogenic and anti-tumoral therapies10
. BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah11
. CSL Biotherapies Awarded US Government Contract for Influenza Pandemic Preparedness and Response